Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Phosphorus or phosphorus compound
Reexamination Certificate
2007-10-11
2010-02-09
Richter, Johann R (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Phosphorus or phosphorus compound
C424S717000, C424S677000, C424S678000, C424S679000, C424S680000, C424S681000, C424S722000, C514S002600, C514S023000, C514S054000, C514S060000, C514S062000, C514S557000, C514S561000, C514S738000, C514S773000, C514S777000, C514S778000, C514S784000, C514S788000
Reexamination Certificate
active
07658952
ABSTRACT:
Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.
REFERENCES:
patent: 6309673 (2001-10-01), Duponchelle et al.
patent: 6537976 (2003-03-01), Gupta
patent: 6689275 (2004-02-01), Gupta
patent: 6779468 (2004-08-01), Gupta
patent: 2005/0142212 (2005-06-01), Gupta
patent: WO9829434 (1998-07-01), None
patent: WO 99/07419 (1999-02-01), None
patent: WO2005044189 (2005-05-01), None
patent: WO2006019843 (2006-02-01), None
patent: WO2007089571 (2007-08-01), None
patent: WO2007089577 (2007-08-01), None
Lomashvili et al., “Phosphate-Induced Vascular Calcification: Role of Pryophosphate and Osteopontin,” J Am Soc Nephrol, vol. 15 (2004) pp. 1392-1401.
Lomashvili et al., “Reduced Plasma Pyrophosphate Levels in Hemodialysis Patients,” J Am Soc Nephrol vol. 16 (2005) pp. 2495-2500.
Fleisch et al., “Inhibition of Aortic Calcification by means of Pyrophosphate and Polyphosphates,” Nature vol. 207 (1965); pp. 100-1301.
Crowther et al., “The Hydrolysis Of The Condensed Phosphates I. Sodium Pyrophosphate And Sodium Triphosphate,” Canadian Journal of Chemistry vol. 32 (1954); pp. 42-48.
Meyer et al., “Calcification Inhibitors In Rate And Human Serum And Plasma,” Biochimica et Biophysica Acta, vol. 799 (1984) pp. 115-121.
El-Abbadi et al., “Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench,” Current Opinion in Nephrology and Hypertension vol. 14 (2005) pp. 519-524.
Towler, “Inorganic Pyrophosphate: A Paracrine Regulator of Vascular Calcification and Smooth Muscle Phenotype,” Arterioscler. Thromb. Vasc. Biol. vol. 25 (2005) pp. 651-654.
Meyere, “Can Biological Calcification Occur in the Presence of Pyrophosphate?, ” Archives of Biochemistry and Biophysics, vol. 231, No. 1, May 15, 1984, pp. 1-8.
Terkeltaub, “Inorganic pyrophosphate generation and disposition in pathophysiology,” Am J Physiol. Cell Physiol, vol. 281 (2001); pp. C1-C11.
Rufenacht et al., “Measurement of inhibitors of calcium phosphate precipitation in plasma ultrafiltrate,” Am J. Physiol vol. 246 (1984) pp. 648-655.
Tuchweber et al., “Effect Of Sodium Pyrophosphate On Experimental Soft-Tissue Calcification And Hypercalcemia,” Canadian Journal Of Physiology And Pharmacology, vol. 45 (1967); pp. 957-964.
Russell et al., “Inorganic Pyrophosphate and Pyrophosphatases in Calcification and Calcium Homeostasis,” Clinical Orthopaedics and Related Research No. 69 (1970); pp. 101-117.
Fleisch et al. “Diphosphonates Inhibit Formation of Calcium Phosphate Crystals in vitro and Pathological Calcification in vivo,” Science vol. 165, (1969) pp. 1264-1266.
Francis, “Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resportion in Tissue Culture and in vivo,” Science vol. 165 (1969) pp. 1262-1264.
Rodan et al., “Bisphosphonates: Mechanisms of Action,” J. Clin. Invest.—The American Society for Clinical Investigation, Inc. vol. 97, No. 12 (1996), pp. 2692-2696.
Fleisch, “Bisphosphonates: Mechanisms of Action,” Endocrine Reviews vol. 19(1) (1998)—Downloaded from edrv. endojournals.org on Jun. 28, 2006.
Nitta et al., “Effects of Cyclic Intermittent Etidronate Therapy on Coronary Artery Calcification in Patients Receiving Long-Term Hemodialysis,” American Journal of Kidney Diseases vol. 44, No. 4 (2004) pp. 680-688.
Karoor Sujatha
Patel Himanshu D.
Riser Bruce L.
Zieske Paul
Baxter Healthcare S.A.
Baxter International Inc.
Choi Frank I
K&L Gates LLP
Richter Johann R
LandOfFree
Dialysis solutions containing pyrophosphates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dialysis solutions containing pyrophosphates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dialysis solutions containing pyrophosphates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211181